Debio 0123-102 (Debiopharm)
Description: A Phase 1, Dose Finding Study of Debio 0123 as Monotherapy in Adult Patients with Advanced Solid Tumors, followed by an Expansion Part to Assess Safety and Preliminary Anti-Tumor Activity
Mechanism of Action: WEE1 inhibitor (suppresses the G2-M checkpoint in the cell cycle)
Target Patient Population: All solid tumors in Dose Escalation
Study Design: Drug is given orally daily.